How we use sources
Regenerative medicine changes quickly. A page can be accurate about a public programme while still being incomplete about today’s foreign-patient access. We therefore separate general evidence, reported clinical pathways and current institutional confirmation.
Sources are prioritised in this order: government or regulator, treating institution or recognised registry, peer-reviewed literature, and then commercial or third-party material as a research lead.
Regulation and clinical status
Regulation on the Administration of Clinical Research and Clinical Translation and Application of New Biomedical TechnologiesChinese government regulation effective 1 May 2026, used to distinguish clinical research from clinical application.Open official source → National Health Commission interpretation and implementation materialsUsed for current interpretation of clinical research, clinical translation and product pathways.National Health Commission → Hainan provincial and Boao Lecheng public informationUsed to identify publicly reported frontier biomedical technology projects and clinical-translation activity.Hainan government → Lung-regeneration pathway
Regend clinical-development and patient informationUsed to understand the publicly described REGEND001 lung-progenitor-cell pipeline, indications and Hainan clinical-translation activity. Company information is cross-checked and does not by itself confirm foreign-patient access.View pipeline → Independent patient-safety guidance
International Society for Stem Cell Research — patient guideIndependent guidance on evaluating stem-cell treatments, claims, evidence, risks and trial participation.About Stem Cells → EuroGCT patient informationExpert-reviewed information on gene and cell therapy, clinical research and disease-specific topics.EuroGCT → Clinical trial registries and peer-reviewed databasesUsed to check study registration, phase, sponsor, institution, recruitment and published evidence.ClinicalTrials.gov → What a source cannot prove
A government announcement, company page, paper or registry entry may support one part of a claim, but it does not automatically prove that an international patient can receive treatment today. Access must still be confirmed with the responsible institution.
Last reviewed: September 2026
Pages are updated as institutional status changes. Contact us if you identify a source that appears outdated or inconsistent.
